pCPA Monthly Trends & Insights – June 30, 2018

July 17, 2018
-

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update

 

The June 30, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are:

  • Three negotiations were completed, while one negotiation was closed for a total of 193 completed negotiations and 26 closed negotiations;
  • Eight new drug products have initiated pCPA negotiations, for a total of 47 active negotiations;
  • No new drug products were added to the “No pCPA Negotiations” list, for a total of 59 products for which the pCPA has declined to negotiate – collectively or at the provincial-territorial level.

 

Negotiation Initiation

 

  • Eight new drug products have initiated pCPA negotiations since the last update, for a total of 47 active negotiations.

 

Brand Name Generic Name Manufacturer Indication Recommendation/ Notification to Implement Date Time to Initiation*
Adcetris Brentuximab vedotin Seattle Genetics Hodgkin’s Lymphoma March 8, 2018 99
Kevzara** Sarilumab Sanofi Genzyme Rheumatoid Arthritis January 12, 2017 N/A
Maviret Glecaprevir/pibrentasvir AbbVie Corporation Hepatitis C January 23, 2018 143
Movapo Apomorphine hydrochloride Paladin Labs Inc. Parkinson’s Disease January 23, 2018 143
Rituxan SC Rituximab Hoffman-La Roche limited Chronic Lymphocytic Leukemia N/A N/A
Toujeo Insulin glargine Sanofi Type 1 and Type 2 Diabetes N/A N/A
Venclexta Venetoclax AbbVie Corporation Chronic Lymphocytic Leukemia March 19, 2018 88
Opdivo in combination with Yervoy Ipilimumab and nivolumab Bristol Myers Squibb Canada Metastatic Melanoma December 15, 2017 182

*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation
**Original negotiation was closed in October 2017

Signals Decoded:

This month sees another file re-initiated after having been previously closed without an agreement (Kevzara), as well as a return to the negotiation table on Rituxan SC, just over a year after the completion of initial negotiations. Also of note is the initiation of negotiations for Opdivo (in combination with Yervoy) for what’s likely the first of several indications; and Maviret, a pan-genotypic treatment option for chronic HCV from AbbVie, whose other HCV therapies have not received wide public funding.

Negotiations Completed/Closed

 

  • Three negotiations were completed since the last update, for a total of 193 completed negotiations.

 

Brand Name Generic Name Manufacturer Indication Negotiation Initiation Duration *
Caprelsa Vandetanib Sanofi Genzyme Medullary thyroid cancer December, 2017 182 days
Ocaliva Obeticholic acid Intercept Pharma Canada Inc. Primary biliary cholangitis December, 2017 182 days
Odefsey Emtricitabine/rilpivirine/

tenofovir/alafenamide

Gilead Sciences Canada Inc. HIV-1 infection August, 2017 304 days

*Approximation: Negotiation initiation and completion date assumed to be mid-month for the purposes of the calculation

 

  • One negotiation was closed since the last update, for a total of 26 closed negotiations.

 

Brand Name Generic Name Manufacturer Indication Negotiation Initiation Duration *
Descovy Emtricitabine/tenofovir/alafenamide Gilead Sciences Canada Inc. HIV-1 Infection August, 2017 304 days

*Approximation: Negotiation initiation and completion date assumed to be mid-month for the purposes of the calculation

Signals Decoded:

Two single tablet regimens for HIV were completed – one successfully, Odefsey, and one closed without a LOI, Descovy. Caprelsa becomes another example of a product which was previously closed without an LOI and which has now been successfully negotiated.

 

Files Under pCPA Consideration

 

In addition to the monthly updates to the pCPA website, MORSE Consulting tracks the number of products “under pCPA Consideration” which have been reviewed by CADTH but have not yet been initiated for negotiation or closed without negotiations.

 

  • Five new drug products received a CDEC or pERC recommendation or notification to implement in June 2018, for a total of approximately 30 products under pCPA Consideration.

 

Brand Name Generic Name Manufacturer Indication Final Recommendation/Notification to Implement
Akynzeo Netupitant/palonosetron Purdue Pharma Nausea and vomiting (chemotherapy induced) prevention Reimburse with clinical criteria and/or conditions
Dupixent Dupilumab Sanofi Genzyme Atopic dermatitis Do not reimburse
Juluca Dolutegravir/rilpivirine ViiV Healthcare HIV Infection Reimburse with clinical criteria and/or conditions
Prevymis Letermovir Merck Canada Cytomegalovirus infection, prophylaxis Reimburse with clinical criteria and/or conditions
Siliq Brodalumab Valeant Canada Psoriasis moderate to severe plaque Reimburse with clinical criteria and/or conditions

 

 

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share